MLAB Stock - Mesa Laboratories, Inc.
Unlock GoAI Insights for MLAB
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $240.98M | $216.19M | $219.08M | $184.34M | $133.94M |
| Gross Profit | $150.87M | $133.25M | $133.69M | $109.09M | $87.01M |
| Gross Margin | 62.6% | 61.6% | 61.0% | 59.2% | 65.0% |
| Operating Income | $16.34M | $-272,075,000 | $3.32M | $4.70M | $12.36M |
| Net Income | $-1,974,000 | $-254,246,000 | $930,000 | $1.87M | $3.27M |
| Net Margin | -0.8% | -117.6% | 0.4% | 1.0% | 2.4% |
| EPS | $-0.36 | $-47.20 | $0.17 | $0.36 | $0.66 |
Mesa Laboratories, Inc. develops, manufactures, and sells life sciences tools and quality control products and services in the United States, Europe, the Asia Pacific, and internationally. The company's Sterilization and Disinfection Control segment manufactures and sells biological, cleaning, and chemical indicators that are used to assess the effectiveness of sterilization and disinfection processes in the hospital, dental, medical device, and pharmaceutical industries. This segment also provides testing and laboratory services primarily to the dental industry. Its Biopharmaceutical Development segment develops, manufactures, and sells automated systems for protein analysis (immunoassays) and peptide synthesis solutions. This segment's solutions include protein analysis comprising analysis equipment, CDs, kits, and buffers; and peptide synthesizers that enables to automate chemically synthesized peptides that are used in the creation of peptide therapies, biomaterials, cosmetics, and general research. The company's Calibration Solutions segment designs, manufactures, and markets quality control and calibration products to measure or calibrate temperature, pressure, pH, humidity, and other such parameters used for health and safety purposes in the hospital, medical device manufacturing, pharmaceutical manufacturing, and various laboratory and healthcare environments. This segment's products include continuous monitoring systems, dialysate meters and consumables, data loggers, gas flow calibration and air sampling equipment, and torque testing systems. Its Clinical Genomics segment develops, manufactures, and sells genetic analysis tools that include MassARRAY system and consumables, including chips, panels, and chemical reagent solutions used by clinical labs to perform genomic clinical testing in several therapeutic areas, such as newborn screenings, pharmacogenetics, and oncology. The company was incorporated in 1982 and is headquartered in Lakewood, Colorado.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| August 7th 2025 | Wells Fargo | Upgrade | Equal Weight | $67 |
| August 28th 2024 | Wells Fargo | Initiation | Underweight | $120 |
| January 4th 2024 | Evercore ISI | Upgrade | Outperform | $125← $100 |
Earnings History & Surprises
MLABEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 26, 2026 | — | — | — | — |
Q1 2026 | Feb 3, 2026 | $2.41 | — | — | — |
Q4 2025 | Nov 6, 2025 | $1.56 | $1.76 | +12.8% | ✓ BEAT |
Q3 2025 | Aug 5, 2025 | $2.46 | $2.32 | -5.7% | ✗ MISS |
Q2 2025 | May 28, 2025 | $2.75 | $2.23 | -18.9% | ✗ MISS |
Q1 2025 | Feb 4, 2025 | $1.41 | $2.67 | +89.4% | ✓ BEAT |
Q4 2024 | Nov 7, 2024 | $2.48 | $2.45 | -1.2% | ✗ MISS |
Q3 2024 | Aug 5, 2024 | $2.33 | $2.83 | +21.5% | ✓ BEAT |
Q2 2024 | Jun 5, 2024 | $-0.11 | $2.77 | +2618.2% | ✓ BEAT |
Q1 2024 | Feb 5, 2024 | $2.04 | $2.02 | -1.0% | ✗ MISS |
Q4 2023 | Nov 6, 2023 | $1.65 | $1.91 | +15.8% | ✓ BEAT |
Q3 2023 | Aug 3, 2023 | $1.67 | $1.77 | +6.0% | ✓ BEAT |
Q2 2023 | May 25, 2023 | $1.98 | $1.94 | -2.0% | ✗ MISS |
Q1 2023 | Feb 6, 2023 | $2.10 | $2.35 | +11.9% | ✓ BEAT |
Q4 2022 | Nov 3, 2022 | $1.39 | $2.88 | +107.2% | ✓ BEAT |
Q3 2022 | Aug 4, 2022 | $1.95 | $1.17 | -40.0% | ✗ MISS |
Q2 2022 | May 31, 2022 | $1.88 | $2.22 | +18.1% | ✓ BEAT |
Q1 2022 | Feb 3, 2022 | $1.68 | $1.36 | -19.0% | ✗ MISS |
Q4 2021 | Nov 4, 2021 | $1.29 | $1.87 | +45.0% | ✓ BEAT |
Q3 2021 | Aug 5, 2021 | $1.36 | $1.28 | -5.9% | ✗ MISS |
Latest News
Wells Fargo Maintains Equal-Weight on Mesa Laboratories, Raises Price Target to $83
➖ NeutralMesa Laboratories Q2 Adj. EPS $2.75, Sales $60.737M Beat $60.733M Estimate
📈 PositiveNutanix And TransUnion Will Replace Acadia Healthcare Company And ManPowerGroup In The S&P MidCap 400, Respectively. Acadia Healthcare And ManPowerGroup Will Replace TechTarget And Mesa Laboratories In The S&P SmallCap 600, Respectively
➖ NeutralMesa Laboratories Repays $97.5M In Convertible Notes Using Credit Agreement Draw
➖ NeutralFrequently Asked Questions about MLAB
What is MLAB's current stock price?
What is the analyst price target for MLAB?
What sector is Mesa Laboratories, Inc. in?
What is MLAB's market cap?
Does MLAB pay dividends?
Similar Stocks
Technology SectorExplore stocks similar to MLAB for comparison